Real world data

Cornerstone AI Taps Viraj Narayanan as Co-CEO to Drive Industry-wide Adoption of Clean Data in Healthcare and Pharmaceuticals

Retrieved on: 
Thursday, April 4, 2024
MCK, Janssen Pharmaceuticals, Organization, Natural language processing, Growth, Narayan (name), Science, Real, Business, University, Patient, SAN, Research, Software, Senior, McKesson Corporation, MBA, Real world data, Drug development, COTA, FDA, Government, Consultant, Carnegie Mellon University, Medical device

SAN FRANCISCO, April 4, 2024 /PRNewswire-PRWeb/ -- Cornerstone AI, makers of a powerful AI software solution that cleans real world healthcare data significantly faster and more accurately than existing solutions, today announced that Viraj Narayanan has joined the company as Co-CEO. Narayanan will work alongside Cornerstone AI founder and Co-CEO Michael Elashoff to scale its highly intelligent, automated software platform which has created unparalleled efficiencies while enabling confidence in the fidelity of data needed to answer critical scientific questions.

Key Points: 
  • "Cornerstone will become the leading utility for data cleaning ," said Narayanan.
  • "Everyone is learning how AI can help organizations run more efficiently than ever before, but in healthcare, nailing the data piece is essential."
  • "We've built a remarkably robust platform to clean healthcare data at scale, without sacrificing the precision and accuracy required in life sciences," said Elashoff.
  • "Now is the time that pharmaceutical companies need to access the insights in Real World Data.

OneMedNet iRWD® Draws Attention at Clinical Trials Meeting

Retrieved on: 
Monday, February 12, 2024
Medical device, Pharma, SCOPE, Real world data, Patient, Organization, Medicine, Health, Real

SCOPE is based on the premise that “Clinical trials and clinical research are essential for advancing medical knowledge, improving patient care, and developing new treatments and therapies for the patients who need them.”

Key Points: 
  • SCOPE is based on the premise that “Clinical trials and clinical research are essential for advancing medical knowledge, improving patient care, and developing new treatments and therapies for the patients who need them.”
    Over 4,000 attendees from 850 organizations and 27 different countries are in attendance to collaborate on solving the challenges of data access and diversity optimization in clinical trials.
  • “We are excited to engage with our existing customers and partner with new ones over the next two days,” stated Aaron Green, OneMedNet President.
  • “These include Clinical Research Organizations and Life Science companies (including Pharma and Medical Device) - who are all highly motivated to expand patient insight using Real World Data.
  • We intend to increase awareness of our solutions that provide seamless access to high quality, de-identified patient data in near real-time.”

Every Cure to Leverage Atropos Health’s GENEVA OS and Evidence Network to Advance the Discovery and Development of Therapies for Underserved Populations

Retrieved on: 
Monday, January 8, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Artificial Intelligence, Other Science, Research, Software, Networks, Health Technology, Science, Data Management, Clinical Trials, Entrepreneurship, Partnership, Heel, Pharmacy, Multimedia, Collection, Synthetic media, Chat, Cell, CRAFT, Disease, Stanford University, Gout, Novartis, AI, Translation, Patient, Real world data, Real, Atropos, Pharmaceutical industry

The collaboration allows Every Cure to leverage GENEVA OS™ and data from the Atropos Evidence™ Network to confirm and enhance findings from their AI driven data platform in the real world.

Key Points: 
  • The collaboration allows Every Cure to leverage GENEVA OS™ and data from the Atropos Evidence™ Network to confirm and enhance findings from their AI driven data platform in the real world.
  • By doing this, it offers key real world signals and generation of AI model features to emulate the effect of therapies in real world populations.
  • Partners like Every Cure will receive access to the Atropos portfolio of evidence generation tools through federated installation of Geneva OS in their internal cloud data environment.
  • CRAFT Emulation Toolkit enables this evidence generation with the same speed-to-insight users have come to expect from Atropos Health.

Atropos Health Partners with Arcadia to Democratize Access to Real World Evidence for Value-Based Care Decision Making

Retrieved on: 
Friday, January 5, 2024
Networks, Managed Care, Health, Artificial Intelligence, Data Management, Hospitals, Health Technology, Technology, Partnership, Heel, Multimedia, Collection, Chat, Synthetic media, CRAFT, Data, AI, Novartis, Translation, Patient, Physiology, Real world data, Real, Atropos, RWE, Nursing

The partnership provides Arcadia’s provider customers with access to the Atropos Health portfolio of evidence generating applications to support whole person care and value-based performance.

Key Points: 
  • The partnership provides Arcadia’s provider customers with access to the Atropos Health portfolio of evidence generating applications to support whole person care and value-based performance.
  • Arcadia customers that subscribe to Atropos Health can help accelerate appropriate clinical decision making to drive high-value, low-cost care for patients based on their unique physiology.
  • In addition, Atropos Health’s Life Sciences users can conduct real-world evidence (RWE) studies leveraging Arcadia’s longitudinal research dataset as part of the Atropos Evidence Network.
  • “This optimization is what Atropos Health delivers across our products, and we're proud to bring the high-quality data Arcadia is known for into the Atropos Evidence Network.

Atropos Health Named to the 2023 CB Insights’ Digital Health 50 List

Retrieved on: 
Tuesday, December 5, 2023
Data Management, Biotechnology, Technology, Professional Services, Health, General Health, Health Technology, Research, Data Analytics, Science, Clinical Trials, Global Reach, Real, Real world data, Organization, Entrepreneurship, Synthetic media, Clinical trial, Traction, CB, Chat, Digital, Drug discovery, CB Insights, Health care, Chin Na, AI, Physician, Digital health, Pharmaceutical industry, Mosaic

CB Insights today named Atropos Health to its fifth-annual Digital Health 50 (formerly the Digital Health 150), showcasing the 50 most promising private digital health companies of 2023.

Key Points: 
  • CB Insights today named Atropos Health to its fifth-annual Digital Health 50 (formerly the Digital Health 150), showcasing the 50 most promising private digital health companies of 2023.
  • "From bringing clinical trials to underserved populations to developing new drugs and therapies, this year’s Digital Health 50 winners are transforming the future of healthcare,” said Alex Lennox-Miller, CB Insights’ Lead Healthcare Analyst.
  • Geneva OS and ChatRWD work alongside Atropos’ evidence solutions – the Green Button Informatics Consult Service, Atropos Evidence Network, and the Atropos Evidence Library.
  • Quick facts on the 2023 Digital Health 50:
    Equity funding and deals: Overall, the cohort has raised $3.2B+ over 145 equity deals since 2018.

Atropos Health Forms Life Science Advisory Board, Increasing Commitment to Accelerated Drug Development and Clinical Trial Diversity and Inclusion

Retrieved on: 
Thursday, November 30, 2023
Biotechnology, Technology, Professional Services, Health, Pharmaceutical, DEI (Diversity, Equity and Inclusion), Research, Data Analytics, Artificial Intelligence, Science, Clinical Trials, Medicine, Translation, Real, Real world data, Organization, Entrepreneurship, Synthetic media, Acceleration, Chat, Drug discovery, PwC, Drug development, Pharmaceutical industry, Moderna, Novartis, AI

“I firmly believe that 2024 will be a revolutionary year in drug discovery and the acceleration of early drug development following the heels of innovation in AI,” said Dr. Brigham Hyde, Co-Founder and CEO Atropos Health.

Key Points: 
  • “I firmly believe that 2024 will be a revolutionary year in drug discovery and the acceleration of early drug development following the heels of innovation in AI,” said Dr. Brigham Hyde, Co-Founder and CEO Atropos Health.
  • They join Dr. Sean Khozin of Braven and Phyusion and Gerry McDougall former Senior Healthcare Consulting Partner at PwC.
  • “By dismantling barriers to accessing data and fostering an exchange of observational insights, Atropos Health is redefining life science clinical trials’ research and delivery,” said Salami.
  • “By democratizing access to essential data, Atropos Health is putting its insight potential into everyone’s hands and leading a powerful paradigm shift.”

Folia Health Announces Groundbreaking Flare Tracking Technology to Bridge Research Gaps and Enhance Chronic Condition Management

Retrieved on: 
Thursday, November 9, 2023
Patient, Health care, MPH, NIH Intramural Research Program, Real world evidence, Sickle cell disease, Real world data, Conditional sentence, Health, Quality of life, Research, RWE, Real, Predictive analytics, Algorithm, Nursing, Pharmaceutical industry, Flare

Folia Health's Flare Tracking Technology provides an innovative solution that reimagines the horizon of acute event management, improving patient care and contributing to vital research endeavors.

Key Points: 
  • Folia Health's Flare Tracking Technology provides an innovative solution that reimagines the horizon of acute event management, improving patient care and contributing to vital research endeavors.
  • 3) Bridging Research Gaps: By analyzing Flare data between clinic visits, Folia Health's technology contributes to the wealth of Real World Evidence (RWE), improving our understanding of chronic diseases and refining treatment strategies.
  • Nell Meosky Luo, Chief Executive Officer and Founder at Folia Health, commented, “Our Flare Tracking Technology represents a significant step forward in the understanding of chronic diseases.
  • To learn more about Folia Health's Flare Tracking Technology and its dual impact on chronic disease management and research, please visit https://www.foliahealth.com/research or reach out to [email protected] .

Introducing Cercle - AI Bridging the Gap in Women's Healthcare

Retrieved on: 
Wednesday, November 8, 2023
Fertility, Knowledge, Woman, FDA, RWD, Roger Hawkins (drummer), Copenhagen, HIPAA, Real world evidence, Genetics, Congress, Medtech, USF, RWE, Research, University of Copenhagen Faculty of Health and Medical Sciences, IVF, Genomics, Real, Medicine, Partnership, University, Privacy, Clinic, AI, Real world data, Patient, Acceleration, Medical imaging, Medical device, Nursing, Cercle

SAN FRANCISCO, Nov. 8, 2023 /PRNewswire/ -- Cercle, an AI technology company unlocking comprehensive and secure data insights for the healthcare industry, announced its launch today. Its technology platform, the Cercle™ Biomedical Graph, is the first and only of its kind, harnessing and connecting billions of anonymized biomedical and genomics data points drawn securely from healthcare clinics and research labs around the world. When channeled through the Cercle™ Biomedical Graph, these data points become a treasure trove of insights for clinics, medical researchers, healthcare providers, patients, and the rest of the healthcare  ecosystem. These data insights can accelerate medical discoveries in the pharmaceutical and research fields, enable the acceleration of precision medicine and personalized treatments, help clinics improve the efficiency and effectiveness of  medical care, and ultimately, drive better health outcomes. The company has already partnered with two trusted healthcare institutions, Eurofins Genoma and US Fertility.

Key Points: 
  • When channeled through the Cercle™ Biomedical Graph, these data points become a treasure trove of insights for clinics, medical researchers, healthcare providers, patients, and the rest of the healthcare  ecosystem.
  • Cercle is launching first in fertility and women's healthcare, ushering in a new age of accuracy, knowledge and clarity in a historically under-researched and under-funded medical field.
  • Cercle utilizes AI technology to harmonize and transform this raw and fragmented data into accurate insights that help improve patient outcomes.
  • Cercle plans to support doctors, clinics, biotech and pharmaceutical researchers, and healthcare communities across many women's healthcare verticals and needs beyond fertility in the future.

Virtusa named a Major Player in IDC MarketScape for Life Sciences R&D RWE, RWD, Platforms, Technologies and Consulting Services

Retrieved on: 
Monday, October 30, 2023
MRI, RWD, Health care, RMIT Platform Technologies Research Institute, Real world data, Head, IDC, Research, HIV disease progression rates, ChromeOS, Consultant, Virtusa, COVID-19, Medicine, X-ray, Pharmaceutical industry, Ultrasound

The COVID-19 pandemic has underscored the critical importance of RWD, showcasing its potential to enhance advanced research capabilities and expedite clinical trials.

Key Points: 
  • The COVID-19 pandemic has underscored the critical importance of RWD, showcasing its potential to enhance advanced research capabilities and expedite clinical trials.
  • Virtusa has recognized the transformative power of RWD and has harnessed it to deliver superior solutions across the Lifesciences industry.
  • We feel that Virtusa's dedication to quality, robustness, and value-driven results sets us apart as a major player in this field."
  • Virtusa remains dedicated to collaborating with the Life Sciences community, providing advanced solutions, and advancing RWD technology.

Atropos Health Launches New Geneva OS and ChatRWD User Application for Rapid Real World Evidence With Generative AI

Retrieved on: 
Thursday, October 5, 2023
Data Management, Practice Management, Technology, Professional Services, Health, Health Technology, Research, Data Analytics, Software, Artificial Intelligence, Science, Multimedia, Chin Na, Real world evidence, Real world data, Doctor of Philosophy, Internet, Real, MBBS, Organization, Ethics, OS, Roger Hawkins (drummer), Safety, Stanford University, Stanford University Medical Center, Entrepreneurship, Synthetic media, ChatGPT, Chat, Literature, ROI, The New York Times, Patient, Mobile phone, Nursing, Medicine

Atropos Health , leader in evidence generation for healthcare, today announced the launch of the Geneva OS™(Generative Evidence Acceleration Operating System) and the ChatRWD™ (Real World Data) application, the first Generative AI application incorporating direct Chat-to-Database capability, to help healthcare and life science leaders advance and accelerate evidence generation.

Key Points: 
  • Atropos Health , leader in evidence generation for healthcare, today announced the launch of the Geneva OS™(Generative Evidence Acceleration Operating System) and the ChatRWD™ (Real World Data) application, the first Generative AI application incorporating direct Chat-to-Database capability, to help healthcare and life science leaders advance and accelerate evidence generation.
  • “In addition, our ChatRWD user application represents an evolutionary jump in the speed and user experience by which evidence can be generated.
  • Users can now access Geneva OS and ChatRWD alongside Atropos’ existing evidence solutions – the Green Button Informatics Consult Service, Atropos Evidence Network, and Atropos Evidence Library.
  • Existing Atropos Health users are already receiving access to Geneva OS and the company is accepting beta users for the ChatRWD application.